{"id":"W4415940075","doi":"10.1016/j.annonc.2025.08.971","title":"548P Phase I/Ib trial of inavolisib (INAVO) + pertuzumab (P) + trastuzumab (H) for PIK3CA-mutated (mut), HER2-positive advanced breast cancer (HER2+ aBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Palbociclib; Fulvestrant; Chemotherapy; Cohort; Breast cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007030174,0.00152177,0.001430084,0.0002919663,0.0003248741,0.001351306,0.0008720131,0.00107558,0.01040582],"category_scores_gemma":[0.0006497354,0.0004730354,0.001266086,0.0002929656,0.0007430388,0.0007754885,0.0004064688,0.003530006,0.002923253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001006619,"about_ca_system_score_gemma":0.00096255,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001459361,"about_ca_topic_score_gemma":0.003801277,"domain_scores_codex":[0.999831,0.00004798155,0.000005437792,0.00003669196,0.00001545546,0.0000633057],"domain_scores_gemma":[0.9997713,0.00003322582,0.00003296725,0.00002216515,0.00001292599,0.0001274802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7194377,0.02063875,0.00278606,0.001166311,0.002139311,0.0003267103,0.0001954668,0.003688231,0.03004526,0.001589211,0.02673618,0.1912508],"study_design_scores_gemma":[0.8303875,0.1407595,0.006545479,0.0001248258,0.0008592021,0.0004138736,0.00009575901,0.001586104,0.002835287,0.001379849,0.01497062,0.00004200023],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9567075,0.006466804,0.001605655,0.003445922,0.001085469,0.00336969,0.006761329,0.0007092657,0.0198483],"genre_scores_gemma":[0.9387928,0.006250362,0.003356229,0.004100974,0.0004118674,0.003092559,0.0131281,0.0001766148,0.03069066],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01040582,"threshold_uncertainty_score":0.0348109,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0452135782774123,"score_gpt":0.4467083163830423,"score_spread":0.40149473810563,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}